Gregory E Peterson

Summary

Publications

  1. ncbi Transitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia
    Gregory Peterson
    Des Moines University, Des Moines, IA, USA
    Hosp Pract (1995) 39:87-95. 2011
  2. ncbi Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Gregory Peterson
    Mercy Center for Public Health Policy and Research, Des Moines University, Des Moines, IA 50314, USA
    Ann Med 44:338-49. 2012
  3. ncbi Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir
    Gregory E Peterson
    Des Moines University, Des Moines, IA 50312, USA
    Curr Med Res Opin 22:2613-9. 2006
  4. ncbi Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir
    Gregory E Peterson
    Curr Med Res Opin 22:2613-9. 2006
  5. ncbi Liraglutide in clinical practice: dosing, safety and efficacy
    G E Peterson
    Diabetes Center, Des Moines, IA, USA
    Int J Clin Pract Suppl 64:35-43. 2010
  6. ncbi A checklist approach to selecting the optimal treatment regimen for a patient with type 2 diabetes
    Gregory E Peterson
    Department of Internal Medicine, Des Moines University, Des Moines, IA, USA
    J Fam Pract 58:S21-5. 2009
  7. ncbi Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study
    Philip Raskin
    University of Texas, Southwestern Medical Center, Dallas, Texas 75390 8858, USA
    Diabetes Care 26:2598-603. 2003

Detail Information

Publications7

  1. ncbi Transitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia
    Gregory Peterson
    Des Moines University, Des Moines, IA, USA
    Hosp Pract (1995) 39:87-95. 2011
    ..More formal studies of treatment regimens for patients with hyperglycemia leaving the hospital are needed to guide care for this group...
  2. ncbi Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Gregory Peterson
    Mercy Center for Public Health Policy and Research, Des Moines University, Des Moines, IA 50314, USA
    Ann Med 44:338-49. 2012
    ..A large number of trials demonstrated benefits of GLP-1 RAs, suggesting they could provide suitable treatment options for patients with T2DM...
  3. ncbi Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir
    Gregory E Peterson
    Des Moines University, Des Moines, IA 50312, USA
    Curr Med Res Opin 22:2613-9. 2006
    ..To review intermediate- and long-acting insulins with specific emphasis on the newer insulin analogs...
  4. ncbi Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir
    Gregory E Peterson
    Curr Med Res Opin 22:2613-9. 2006
    ..CONCLUSION: The newer long-acting insulin analogs, insulin detemir and glargine, appear to provide better glycemic control than NPH insulin without increasing the risk of hypoglycemia...
  5. ncbi Liraglutide in clinical practice: dosing, safety and efficacy
    G E Peterson
    Diabetes Center, Des Moines, IA, USA
    Int J Clin Pract Suppl 64:35-43. 2010
    ..This article reviews practical issues that healthcare providers need to consider when implementing therapy with the once-daily glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide...
  6. ncbi A checklist approach to selecting the optimal treatment regimen for a patient with type 2 diabetes
    Gregory E Peterson
    Department of Internal Medicine, Des Moines University, Des Moines, IA, USA
    J Fam Pract 58:S21-5. 2009
    ..A checklist of factors to be considered can be helpful in individualizing treatment for optimal effectiveness based on each patient's needs, concerns, and capabilities...
  7. ncbi Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study
    Philip Raskin
    University of Texas, Southwestern Medical Center, Dallas, Texas 75390 8858, USA
    Diabetes Care 26:2598-603. 2003
    ..Compare the efficacy, safety, and patient satisfaction of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy for patients with type 2 diabetes...